Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (DE:1NE0)
FRANKFURT:1NE0
1NE0 Stock Chart & Stats
€5.05
--
Market closed
€5.05
--
Day’s Range― - ―
52-Week Range€2.78 - €8.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)87.00
Market Cap
$91.68M
Enterprise Value€36.57M
Total Cash (Recent Filing)$30.15M
Total Debt (Recent Filing)$1.63M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 12, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding17,178,785
10 Day Avg. Volume0
30 Day Avg. Volume87
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit1.10
Enterprise Value/Ebitda-3.83
Forecast
1Y Price Target
$16.13Price Target Upside219.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.39
Revenue Forecast (FY)$24.48M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAdvancement of a late-stage clinical trial for a common warts treatment could expand approved indications and open a larger addressable market if the trial meets its endpoints.
Commercial Financing And LeadershipA financing round enabled hiring of a chief commercial officer and funding for sales-force optimization, positioning the company to scale commercial operations and improve revenue growth.
Market Share Via Supply DynamicsIncreasing prescribing of the approved product, together with supply and consistency challenges for compounded alternatives, supports potential market share gains as demand rises.
Bears Say
Analyst Sentiment And RatingAn analyst maintaining a Hold rating could restrain buying momentum until more consistent sales growth provides justification for an upgrade.
Execution And Valuation RiskThe investment thesis depends on proving sustained adoption and execution, and potential additional indications are not yet reflected in the valuation, limiting upside until key milestones are achieved.
Sales Performance VolatilitySales for the flagship product remain inconsistent and have underperformed relative to the initial launch, creating uncertainty around sustainable revenue growth.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €2.78 and its highest was €8.80 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $91.68M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 57 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Mar 11, 2026. The company reported -€0.493 earnings per share for the quarter, beating the consensus estimate of -€0.634 by €0.14.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.36.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.493 in its last earnings report, beating expectations of -€0.634. Following the earnings report the stock price went up 2.101%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1NE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.13 (219.46% Upside)
$16.13 (219.46% Upside)
Blogger Sentiment
Bullish
DE:1NE0 Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.36%
12-Months-Change
Fundamentals
Return on Equity
252.30%
Trailing 12-Months
Asset Growth
-12.99%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
1NE0 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in YCANTH dispensations, strategic partnerships, and positive regulatory feedback, offset by challenges like seasonality impacts and a lengthy EU filing process.View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
€16.13
▲(219.46% Upside)